Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Outcomes of HCT and CAR-T recipients after developing COVID-19

Muhammad Bilal Abid, MD, MRCP, Medical College of Wisconsin, Milwaukee, WI, discusses the poor outcomes associated with hematopoietic cell transplantation (HCT) and CAR-T recipients who develop COVID-19. In his discussion, Dr Abid explains that multiple analyses have found high percentages of COVID-19 attributable mortality rates in these patients. Dr Abid then explains some of the reasons why CAR-T recipients have such poor outcomes, including patient-related factors, disease-related factors, and intensity of lymphodepleting chemotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).